NLM Digital Collections

Search

Start Over Subjects Prescription Drugs -- economics ✖Remove constraint Subjects: Prescription Drugs -- economics Languages English ✖Remove constraint Languages: English

47. One percent of drugs with Medicaid reimbursement were not FDA-approved

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, May 2019
Subject(s):
Drug Approval
Insurance, Health, Reimbursement -- economics
Insurance, Health, Reimbursement -- statistics & numerical data
Medicaid -- economics
Medicaid -- statistics & numerical data
Economics, Pharmaceutical
Fraud -- prevention & control
Prescription Drugs -- economics
Humans
United States
United States. Food and Drug Administration.

48. Rebates for brand-name drugs in Part D substantially reduced the growth in spending from 2011 to 2015

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2019
Subject(s):
Drug Costs -- statistics & numerical data
Drug Costs -- trends
Insurance, Health, Reimbursement -- statistics & numerical data
Insurance, Health, Reimbursement -- trends
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
Medicare Part D -- trends
Economics, Pharmaceutical -- statistics & numerical data
Economics, Pharmaceutical -- trends
Forecasting
Prescription Drugs -- economics
Humans
United States

50. Medicare Part D: CMS should monitor effects of rebates on drug coverage and spending : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

Publication:
Washington, DC : United States Government Accountability Office, September 19, 2023
Subject(s):
Government Regulation
Legislation, Medical
Medicare Part D -- economics
Medicare Part D -- organization & administration
Prescription Drugs -- economics
United States